Go to content
UR Home

Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy

URN to cite this document:
DOI to cite this document:
Tafelmeier, Maria ; Baessler, Andrea ; Wagner, Stefan ; Unsöld, Bernhard ; Preveden, Andrej ; Barlocco, Fausto ; Tomberli, Alessia ; Popovic, Dejana ; Brennan, Paul ; MacGowan, Guy A. ; Ristic, Arsen ; Velicki, Lazar ; Olivotto, Iacopo ; Jakovljevic, Djordje G. ; Maier, Lars S.
License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 18 Jun 2020 15:00


Background Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with a broad spectrum of disease severity. HCM ranges from a benign course to a progressive disorder characterized by angina, heart failure, malignant arrhythmia, syncope, or sudden cardiac death. So far, no medical treatment has reliably shown to halt or reverse progression of HCM or to alleviate its ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons